Highlights
- Significant revenue drop to AU$197.1k from 1H 2024.
- Net loss increased by 61% from the previous year.
- Shares gained a slight increase over the past week.
The financial landscape of Firebrick Pharma (ASX:FRE) for the First Half of 2025 reveals some challenging developments. The company's revenue took a significant dip, down by 89% to AU$197.1k compared to the same period in 2024. Meanwhile, the net loss expanded by 61%, amounting to AU$1.45 million, marking a further struggle in meeting financial targets.
Additionally, the loss per share increased from AU$0.005 to AU$0.007, indicating a deteriorating financial position over the year. Despite these challenges, Firebrick Pharma's shares have shown a modest 1.2% gain from a week ago, noting some positive movement in the market.
Investors are advised to take note of the risk analyses as there are currently five warning signs associated with Firebrick Pharma, three of which are of particular concern. However, potential opportunities may be found using the new AI Stock Screener, which looks at various metrics to discover investment avenues.
For those interested in a deeper dive, the AI Stock Screener can help identify areas like dividend powerhouses, undervalued small caps with insider buying, and high-growth tech and AI companies. This tool allows users to customize their insights, using over 50 available metrics.
Stay informed and explore opportunities with the AI Stock Screener now available. It's crucial to note that all analyses are driven by historical data and current analyst forecasts, and are not personalized to individual financial situations or objectives.